Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals is set to unveil results from its Phase 2 SPRINGBOARD study on an osteoarthritis knee treatment at the prestigious EULAR European Congress of Rheumatology in Vienna. The presentation will detail the efficacy of their long-acting intra-articular injection, EP-104IAR, showcasing its potential to meet a significant unmet medical need. The company’s innovative DiffuSphere technology promises targeted, extended-release drug delivery, aiming to provide patients with prolonged relief and minimal side effects.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
